Concurrent Investment Advisors LLC Acquires 29,322 Shares of Pfizer Inc. (NYSE:PFE)

Concurrent Investment Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 19.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 180,112 shares of the biopharmaceutical company's stock after purchasing an additional 29,322 shares during the period. Concurrent Investment Advisors LLC's holdings in Pfizer were worth $4,564,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in PFE. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the 4th quarter worth about $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Jefferies Financial Group boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. BMO Capital Markets decreased their price objective on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Bank of America boosted their target price on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Leerink Partners cut their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. Finally, Wolfe Research increased their price objective on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Stock Down 0.5%

Shares of NYSE PFE traded down $0.14 during mid-day trading on Monday, hitting $25.25. The company had a trading volume of 11,159,506 shares, compared to its average volume of 45,879,043. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a 50-day simple moving average of $23.72 and a two-hundred day simple moving average of $24.81. The company has a market capitalization of $143.53 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.82 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.81%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.